Onco-Innovations Ltd. (CBOE CA: ONCO) (OTCQB: ONNVF) (FSE: W1H) is making significant strides in preparing its preclinical oncology candidate, ONC010, for clinical development. The company, focused on cancer research and treatment, is developing ONC010, a nanoparticle-encapsulated PNKP inhibitor designed to disrupt DNA-repair mechanisms that cancer cells rely on for survival and resistance to treatment. This approach could potentially lead to more effective therapies for solid tumors, addressing a critical unmet need in oncology.
The significance of Onco-Innovations' recent achievements lies in their collective impact on advancing ONC010 toward human trials. The company has completed a 300-gram API scale-up with approximately 99.3% purity, a crucial step for ensuring consistent and high-quality drug supply for clinical studies. Additionally, a partnership with Nanosoft Polymers is expanding manufacturing capabilities, further strengthening the production infrastructure. These developments are essential for meeting regulatory requirements and supporting future clinical trials.
Onco-Innovations is also progressing with metabolism, analytical, and licensing activities, all part of the investigational new drug (IND)-enabling process. To fund these efforts, the company has arranged approximately CAD$5 million in institutional financing, to be released through 18 monthly tranches. This financing will support ONC010 development, the SynoGraph platform, and general corporate needs. While the eventual proceeds may differ from the stated notional amount, this funding provides a solid financial foundation for the company's near-term objectives.
The appointment of Dave Antony as Chief Financial Officer adds valuable financial and corporate experience to the leadership team. With a planned Phase 1 study of ONC010 in Australia on the horizon, Onco-Innovations is positioning itself to enter the clinic with a well-prepared candidate and the necessary resources. For more details on the company's progress, see the full article at https://nnw.fm/YPLe7.
Onco-Innovations' mission is to pursue the prevention and treatment of cancer through pioneering research and innovative solutions. The company has secured an exclusive worldwide license to patented technology targeting solid tumors. For more information, visit the company's website at https://oncoinnovations.com/. The latest news and updates relating to ONNVF are available in the company's newsroom at https://nnw.fm/ONNVF.
This announcement was disseminated by NetworkNewsWire, a specialized communications platform focused on financial news and content distribution. NetworkNewsWire is part of the Dynamic Brand Portfolio at IBN, which offers services such as wire distribution through InvestorWire, editorial syndication to 5,000+ outlets, press release enhancement, and social media distribution.
